Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Yanghe Decoction (JWYHD) is an optimized Traditional Chinese Medicine (TCM) formulation derived from the classical Yanghe Decoction (Yanghe Tang). It is traditionally used in clinical practice for the treatment of autoimmune diseases, asthma, and granulomatous disorders such as sarcoidosis and mastitis. Pharmacologically, JWYHD is categorized as a botanical drug combination that modulates the tumor immune microenvironment. Recent studies in non-small cell lung cancer (NSCLC) suggest that JWYHD can enhance the efficacy of radiotherapy by upregulating the expression of chemokines CXCL9 and CXCL11. This upregulation promotes the recruitment and infiltration of CD8+ T cells into the tumor, thereby augmenting the anti-tumor immune response. The formula typically consists of the base Yanghe Decoction ingredients modified with additional herbs to enhance its therapeutic range.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiawei Yanghe Decoction.